Contributions to Hypertension With Androgen Deprivation Therapy
Status:
Not yet recruiting
Trial end date:
2028-03-31
Target enrollment:
Participant gender:
Summary
This study plans to learn more about contributors to high blood pressure in men who undergo
androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most
common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary
treatment is through the use of ADT. However, ADT increases the likelihood of developing
heart disease including high blood pressure. This study will determine if dysfunction of the
nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a
significant role in control of blood pressure. The results from this study will help us
understand the ways in which ADT contributes to heart disease and help us develop therapies
to prevent heart disease in prostate cancer survivors.